

## **NEW U.S. PATENT ALLOWANCE GRANTED TO AXIM® BIOTECH FOR USE OF ALL CANNABINOIDS IN ITS CONTROLLED RELEASE CHEWING GUM PRODUCTS**

*Allows Award-Winning Cannabinoid Release Chewing Gum Products to be Used as Delivery Mechanism for All Cannabinoids, Including THC, CBD, CBG, etc.*

**NEW YORK – Nov 16, 2016 – [AXIM® Biotechnologies, Inc. \(AXIM® Biotech\)](#)**

(OTC:AXIM), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number [9,433,601](#), a patent that claims the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from the application, filed in April 2015. This patent covers the inclusion of all cannabinoids (both natural and synthetic) in a chewing gum delivery system, including Tetrahydrocannabinol (THC), all of which may be incorporated in the Company's chewing gum products.

This new patent is an extension of AXIM® Biotech's patent for chewing gum as delivery methods for cannabidiol (Chewing Gum Compositions Comprising Cannabinoids). Prior to this new allowance, Patent [9,023,322](#) only claimed gum products as a delivery mechanism for cannabidiol (CBD), a well-known cannabinoid.

"This new patent is paramount for our company as it provides us with the intellectual property protection to include any of the at least 85 different cannabinoid compounds found in the cannabis plant, including CBD and THC, into our multiple cannabinoid-containing controlled-release chewing gum products," said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. "Acquiring this new patent is also strategically important for AXIM's mission to find cannabinoid-derived solutions for health conditions with no known cure. Furthermore, it gives us exclusive protection on the cannabis pharma and nutraceutical market, which means that no other entities can attempt to introduce a rival product with the same delivery system made with any cannabinoids."

AXIM® Biotech developed the patents it now owns for chewing gum as a delivery method for cannabinoids into two separate products. Its CBD-only CanChew® gum is marketed and is legal to purchase wherever CBD hemp oil products are sold. [AXIM® Biotech](#) holds the exclusive rights to market and distribute CanChew® Gum globally. CanChew® is a botanical hemp-derived CBD chewing gum with a unique oral mucosal absorbance delivery system. Features listed on the CanChew® website include:

- Non-habit forming
- No prescription needed
- Available in all 50 states
- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher

In addition, AXIM® will start [clinical trials](#) for its combination CBD/THC gum, MedChew® Rx, for the treatment of pain and spasticity associated with multiple sclerosis. Directly compared to a sublingually delivered cannabis-based product currently on the market for MS, the estimated market size for MedChew® Rx is \$4.8 billion USD. MedChew® Rx is on track to be fully registered by the EMA and FDA.

AXIM has also developed CanChew Plus™ CBD containing gum with improved delivery system and doses of 10 mg of CBD and 30mg of CBD. Besides these, AXIM has developed CanChew Rx™, which is based on pharmaceutical-grade, 99.9% pure CBD crystals, extracted and manufactured based on company IPs and containing 10, 30, 50, 100 and 150 mg of CBD in microencapsulated form (AXIM IP) for significantly increased bioavailability of the Active Pharmaceutical Ingredient.

Another AXIM® Biotech patent-pending cannabis innovation in clinical trials is AX-1602. The first of its kind, AX-1602 contains CBG (cannabigerol) and other cannabinoids as a treatment for psoriasis and atopic dermatitis.

AXIM® Biotech's core belief is responsibility for environmental stewardship combined with development of innovative products to address conditions with no currently known effective treatment including: Parkinson's disease, Alzheimer's disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.

###

## **About AXIM**

AXIM® Biotechnologies, Inc. (OTC: [AXIM](#)) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit [www.AXIMBiotech.com](http://www.AXIMBiotech.com).

### **FORWARD-LOOKING DISCLAIMER**

*This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.*

## *LEGAL DISCLOSURE*

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

### **Public Relations Contact**

#### **Andrew Hard**

Chief Executive Officer

CMW Media

[andrew.hard@cmwmedia.com](mailto:andrew.hard@cmwmedia.com)

P. +1888 829-0070

[www.cmwmedia.com](http://www.cmwmedia.com)

### **Investor Relations Contact**

#### **Shiwei Yin, Grayling**

[Shiwei.Yin@grayling.com](mailto:Shiwei.Yin@grayling.com)

P. +1646 824-2857

#### **Lucia Domville, Grayling**

[lucia.domville@grayling.com](mailto:lucia.domville@grayling.com)

P. +1646 284-9416

### **Corporate Contact Info**

North American Address:

18 East 50th Street, 5 Floor

New York, NY 10022

+1 844 294 6246

European Address:

Boelewerf 32, Unit 3

2987 VD Ridderkerk, The Netherlands

+31 10 8209 227